|
melanoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The identification of the role of RasGRP3 in melanoma highlights its importance, as a Ras activator, in the phosphoinositide signaling pathway in human melanoma and provides a new potential therapeutic target.
|
21602881 |
2011 |
|
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
RasGRP3 expression was elevated in multiple human prostate tumor tissue samples and in the human androgen-independent prostate cancer cell lines PC-3 and DU 145 compared with the androgen-dependent prostate cancer cell line LNCaP.
|
20876802 |
2010 |
|
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
RasGRP3 expression was elevated in multiple human prostate tumor tissue samples and in the human androgen-independent prostate cancer cell lines PC-3 and DU 145 compared with the androgen-dependent prostate cancer cell line LNCaP.
|
20876802 |
2010 |
|
Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The molecular profiling of MB into 4 major subgroups (WNT, SHH, Grp3, and Grp4) emphasizes the heterogeneity of MB and opens paths in which treatments may be targeted to molecularly aggressive and distinct tumors.
|
30626740 |
2019 |
|
Childhood Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The molecular profiling of MB into 4 major subgroups (WNT, SHH, Grp3, and Grp4) emphasizes the heterogeneity of MB and opens paths in which treatments may be targeted to molecularly aggressive and distinct tumors.
|
30626740 |
2019 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The molecular profiling of MB into 4 major subgroups (WNT, SHH, Grp3, and Grp4) emphasizes the heterogeneity of MB and opens paths in which treatments may be targeted to molecularly aggressive and distinct tumors.
|
30626740 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
A somatic mutation of RasGRP3 decreases Na<sup>+</sup>/I<sup>-</sup> symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway.
|
30323976 |
2018 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In human UM cell lines and murine models, RasGRP3 is specifically required for GNAQ/GNA11-driven Ras activation and tumorigenesis.
|
29490280 |
2018 |
|
Secondary Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
A somatic mutation of RasGRP3 decreases Na<sup>+</sup>/I<sup>-</sup> symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway.
|
30323976 |
2018 |
|
Papillary thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
RasGRP3 may serve as a potential new therapeutic target for PTC.
|
28864115 |
2017 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RasGRP3 expression was upregulated in GBM specimens and glioma stem cells compared with normal brains and neural stem cells, respectively.
|
25682201 |
2015 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RasGRP3 expression was upregulated in GBM specimens and glioma stem cells compared with normal brains and neural stem cells, respectively.
|
25682201 |
2015 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RasGRP3 expression was upregulated in GBM specimens and glioma stem cells compared with normal brains and neural stem cells, respectively.
|
25682201 |
2015 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the putative alteration of expression and potential function of RasGRP3 in the formation and progression of human breast cancer.
|
24779681 |
2014 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
This study was undertaken to investigate the expression of guanyl nucleotide-releasing protein for Ras 3 (RasGRP3) in the cell lines and tissues in BPH and prostate cancer (PCa), as well as its associations with cancer invasion and prognosis in prostate carcinomas.
|
24418912 |
2014 |
|
Severe Combined Immunodeficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
To observe the RasGRP3 function in tumor formation, the Severe combined immunodeficiency (SCID) mouse model was used.
|
24779681 |
2014 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the putative alteration of expression and potential function of RasGRP3 in the formation and progression of human breast cancer.
|
24779681 |
2014 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
This study was undertaken to investigate the expression of guanyl nucleotide-releasing protein for Ras 3 (RasGRP3) in the cell lines and tissues in BPH and prostate cancer (PCa), as well as its associations with cancer invasion and prognosis in prostate carcinomas.
|
24418912 |
2014 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
RasGRP3 expression was elevated in human breast tumor tissue samples as well as in multiple human breast cancer cell lines.
|
24779681 |
2014 |
|
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reduced expression of GNMT in mouse hepatoma cells and human HCC cells appears to increase activity of LKB1 and RAS; activation of RAS signaling to LKB1 and RASGRP3, via ERK and p90RSK, might be involved in liver carcinogenesis and be used as a prognostic marker.
|
22687285 |
2012 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reduced levels of GNMT and phosphorylation of AMPKα at Thr172 and increased levels of Ras, LKB1, and RASGRP3 in HCC samples from patients were associated with shorter survival times.
|
22687285 |
2012 |
|
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
RasGRP3 suppression also inhibited cell proliferation and reduced both colony formation in soft agar and xenograft tumor growth in immunodeficient mice, demonstrating the importance of RasGRP3 for the transformed phenotype of the melanoma cells.
|
21602881 |
2011 |
|
Nephritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Significant associations were found for the single nucleotide polymorphism rs10036748 of TNIP1 with photosensitivity (odds ratio (OR) = 0.87, p = 0.01) and vasculitis (OR = 1.18, p = 0.04); rs10847697 of SLC15A4 with discoid rash (OR = 1.18, p = 0.02); rs6590330 of ETS1 with SLE of age at diagnosis <20 years (OR = 1.24, p = 8.91 x 10(-5)); rs13385731 of RasGRP3 with malar rash (OR = 1.20, p = 0.01), discoid rash (OR = 0.78, p = 0.02) and ANA (OR = 0.72, p = 0.004); rs4917014 of IKZF1 with renal nephritis (OR = 1.13, p = 0.02) and malar rash (OR = 0.83, p = 0.00038), respectively.
|
20516000 |
2010 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
RasGRP3 expression was elevated in multiple human prostate tumor tissue samples and in the human androgen-independent prostate cancer cell lines PC-3 and DU 145 compared with the androgen-dependent prostate cancer cell line LNCaP.
|
20876802 |
2010 |
|
Vasculitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Significant associations were found for the single nucleotide polymorphism rs10036748 of TNIP1 with photosensitivity (odds ratio (OR) = 0.87, p = 0.01) and vasculitis (OR = 1.18, p = 0.04); rs10847697 of SLC15A4 with discoid rash (OR = 1.18, p = 0.02); rs6590330 of ETS1 with SLE of age at diagnosis <20 years (OR = 1.24, p = 8.91 x 10(-5)); rs13385731 of RasGRP3 with malar rash (OR = 1.20, p = 0.01), discoid rash (OR = 0.78, p = 0.02) and ANA (OR = 0.72, p = 0.004); rs4917014 of IKZF1 with renal nephritis (OR = 1.13, p = 0.02) and malar rash (OR = 0.83, p = 0.00038), respectively.
|
20516000 |
2010 |